Back to discover
Disease

Bacterial Infections

Late-stage therapeutic developmentActively researchedRising momentum
44
Publications
19
Clinical trials
10
Related conditions
12
Associated genes
2
Related proteins
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

A Randomized Trial Investigating the Superiority of TDM-optimized Teicoplanin Dosing Versus Standard of Care

Clinical trial2026-08-12Status changed to Terminated · ClinicalTrials.gov

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Clinical Milestones8View
Activity timeline8

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Delafloxacinapproved

Approval — Quofenix is indicated for the treatment of the following infections in adults: acute bac… (2019)

Approval — Xydalba is indicated for the treatment of acute bacterial skin and skin structure infecti… (2015)

Tedizolidapproved

Approval — Sivextro tablets are indicated for the treatment of acute bacterial skin and skin structu… (2015)

Filgrastimapproved

Approval — Filgrastim is indicated for the reduction in the duration of neutropenia and the incidenc… (2010)

Clinical trials

17 sponsors · 1 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
19
All trials
6
Active
13
Late-stage
6
Completed
Late-stage studies
Recruiting
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2019emaApprovalDelafloxacin· Quofenix is indicated for the treatment of the following infections in adults: acute bacterial skin and skin structure infections (ABSSSI), community-acquired pneumonia (CAP), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents. source ↗
2015emaApprovalTedizolid· Sivextro tablets are indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults, adolescents and children weighing at least 35 kg.Consideration should be given to official guidance on the appropriate use of antibacterial agents. Sivextro powder for concentrate for solution for infusion is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) from birth. Consideration should be given to official guidance on the appropriate use of antibacterial agents. source ↗
2015emaApprovalDalbavancin hydrochloride· Xydalba is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients from birth (see sections 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. source ↗
2010emaApprovalFilgrastim· Filgrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy. Filgrastim is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs). In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ?0.5 x 109/l and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events. Filgrastim is indicated for the treatment of persistent neutropenia (ANC ?1.0 x 109/l) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

44 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20132025
Most influential
Recent publications
Major themes8
  • Bacterial Infections10
  • Drug Resistance, Bacterial5
  • Bacteria3
  • Global Health3
  • Anti-Infective Agents2
  • Extracellular Vesicles2
  • Host-Pathogen Interactions2
  • Microbiota2
Leading journals6
  • Emerging infectious diseases3
  • International journal of molecular sciences3
  • Lancet (London, England)3
  • FEMS microbiology reviews2
  • Frontiers in public health2
  • The Lancet. Infectious diseases2
Leading researchers8
  • Liu Y2
  • Abbas K1
  • Adler Y1
  • Alloisio G1
  • Alvarez-Uria G1
  • Amin-Chowdhury Z1
  • Antunes LCM1
  • Ascenzi P1
Affiliations (unnormalised)6
  • Centre for Tropical Medicine and Global Health2
  • Department of Laboratory Medicine2
  • Oxford University Clinical Research Unit2
  • Akershus University Hospital1
  • Amsterdam University Medical Center1
  • Angkor Hospital for Children1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

Disease biology

2 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Related conditions

10 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Bacterial infections are infections caused by bacteria, or infections in which bacteria are the unspecified causative agents. The literature grounding emphasizes their relevance across microbiology, transmission, mortality, prevention and control, and treatment. It also highlights that bacterial infections can involve host-pathogen interactions, adhesion, quorum sensing, microbiota, symbiosis, and biofilm formation.

Causes

The grounding supports bacterial infection as being caused by bacteria in general, without specifying a single organism or syndrome. It also indicates that transmission and persistence on inanimate surfaces can contribute to spread in nosocomial settings. Antimicrobial resistance is not a cause of infection itself, but it is a major feature of bacterial pathogens that complicates treatment and burden.

Pathophysiology

Bacterial infections involve interactions between bacteria and the host, including adhesion to surfaces or tissues, quorum sensing, and biofilm formation. Biofilms create structured microbial communities with an extracellular matrix, altered gene expression, and reduced growth rates, which can support persistence and genetic exchange. Host immune responses, including IL-10-mediated suppression of Th1 cells, NK cells, and macrophages, can also influence pathogen clearance and tissue damage during infection.

Risk factors

The grounding supports exposure to contaminated inanimate surfaces and nosocomial environments as risk factors for acquisition and persistence of bacterial pathogens. Biofilm-associated settings and device-related infections are also highlighted as important contexts for infection. Antimicrobial resistance increases the burden and complicates management, but the supplied material does not support broader patient-level risk factors.

Current standard of care

Treatment is described at the level of drug therapy and therapy, with antibiotics as the central modality for bacterial infections. The grounding also supports prevention and control measures, including approaches aimed at transmission reduction and infection control in healthcare settings. Because antimicrobial resistance is a major issue, the literature also points to antimicrobial stewardship and development of new antibacterial agents or anti-virulence strategies such as quorum-sensing inhibition.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Infections by bacteria, general or unspecified.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.